Home
Vertex and TreeFrog Therapeutics Announced Licensing Agreement and Collaboration to Optimize Production of Vertex Cell Therapies for Type 1 Diabetes

Vertex and TreeFrog Therapeutics Announced Licensing Agreement and Collaboration to Optimize Production of Vertex Cell Therapies for Type 1 Diabetes

Impacting News April 25, 2024

Vertex Pharmaceuticals and TreeFrog Therapeutics in the NEWS

Vertex Pharmaceuticals  (VRTX) and TreeFrog Therapeutics announced that Vertex has obtained an exclusive license to TreeFrog’s proprietary cell manufacturing technology, C-StemTM, to optimize production of Vertex’s cell therapies for Type 1 diabetes (T1D).

TreeFrog and Vertex will collaborate to scale up TreeFrog’s process to produce and amplify cells for . . .

This content is for paid subscribers.
Please click here to subscribe or here to log in.
Impacting News
,
April 25, 2024

Other Articles